BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou Z, Jin H, Ju H, Sun M, Chen H, Li L. Circulating Trimethylamine-N-Oxide and Risk of All-Cause and Cardiovascular Mortality in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Front Med 2022;9:828343. [DOI: 10.3389/fmed.2022.828343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol 2022; 28(39): 5691-5706 [DOI: 10.3748/wjg.v28.i39.5691] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Zixin Y, Lulu C, Xiangchang Z, Qing F, Binjie Z, Chunyang L, Tai R, Dongsheng O. TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review. Front Pharmacol 2022;13:929262. [DOI: 10.3389/fphar.2022.929262] [Reference Citation Analysis]
3 Hsu BG, Wang CH, Lin YL, Lai YH, Tsai JP. Serum Trimethylamine N-Oxide Level Is Associated with Peripheral Arterial Stiffness in Advanced Non-Dialysis Chronic Kidney Disease Patients. Toxins (Basel) 2022;14:526. [PMID: 36006188 DOI: 10.3390/toxins14080526] [Cited by in F6Publishing: 1] [Reference Citation Analysis]